MARKET

TXMD

TXMD

TherapeuticsMD
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.640
+0.030
+1.86%
Opening 12:57 02/24 EST
OPEN
1.630
PREV CLOSE
1.610
HIGH
1.670
LOW
1.610
VOLUME
4.22M
TURNOVER
--
52 WEEK HIGH
2.750
52 WEEK LOW
0.8530
MARKET CAP
636.03M
P/E (TTM)
-2.3131
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
TherapeuticsMD to Report Fourth Quarter 2020 Results on March 2, 2021
4Q date announcement press release
Business Wire · 20h ago
TherapeuticsMD Inc. stock underperforms Monday when compared to competitors
Shares of TherapeuticsMD Inc. shed 4.52% to $1.69 Monday, on what proved to be an all-around mixed trading session for the stock market, with the Dow Jones...
marketwatch.com · 1d ago
TherapeuticsMD Inc. stock rises Friday, outperforms market
Shares of TherapeuticsMD Inc. rose 1.14% to $1.77 Friday, on what proved to be an all-around favorable trading session for the stock market, with the NASDAQ...
marketwatch.com · 4d ago
TherapeuticsMD Inc. stock underperforms Thursday when compared to competitors
Shares of TherapeuticsMD Inc. shed 5.41% to $1.75 Thursday, on what proved to be an all-around poor trading session for the stock market, with the NASDAQ...
marketwatch.com · 5d ago
TherapeuticsMD Inc. stock falls Wednesday, still outperforms market
Shares of TherapeuticsMD Inc. slid 0.54% to $1.85 Wednesday, on what proved to be an all-around mixed trading session for the stock market, with the Dow...
marketwatch.com · 6d ago
TherapeuticsMD Announces Closing of its Underwritten Public Offering of Common Stock
TherapeuticsMD, Inc. (NASDAQ:TXMD) today announced the closing of its underwritten public offering of 59,459,460 shares of its common stock for net proceeds of approximately $97.1 million, after deducting underwriting discounts and commissions and estimate...
Business Wire · 02/16 21:01
What the GameStop Congressional hearing will reveal to retail investors
A House Financial Services Committee hearing about the GameStop trading frenzy, scheduled for Feb. 18, will shine a light on Robinhood and stock trading.
Yahoo Finance · 02/16 17:02
8-K: TherapeuticsMD, Inc.
(EDGAR Online via COMTEX) -- 0000025743 false 0000025743 2021-02-11 2021-02-11 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND...
Edgar Online - (EDK = 8-Ks/S1/S-4) · 02/16 15:53
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of TXMD. Analyze the recent business situations of TherapeuticsMD through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 6 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average TXMD stock price target is 6.67 with a high estimate of 10.00 and a low estimate of 3.000.
EPS
Institutional Holdings
Institutions: 264
Institutional Holdings: 177.89M
% Owned: 45.87%
Shares Outstanding: 387.83M
TypeInstitutionsShares
Increased
45
18.99M
New
40
9.36M
Decreased
38
25.24M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
+1.27%
Pharmaceuticals & Medical Research
+1.40%
Key Executives
Chairman/Independent Director
Tommy Thompson
President/Secretary
John Milligan
Chief Executive Officer/Director
Robert Finizio
Co-Founder
Brian Bernick
Chief Financial Officer
James D'Arecca
Chief Information Officer
Adam Miller
Chief Compliance Officer
John Knighton
Vice President - Finance
Michael Donegan
General Counsel
Marlan Walker
Other
Dawn Halkuff
Other
Mitchell Krassan
Other
Sebastian Mirkin
Other
Bharat Warrier
Independent Director
Paul Bisaro
Independent Director
J. Martin Carroll
Independent Director
Cooper Collins
Independent Director
Karen Ling
Independent Director
Jules Musing
Independent Director
Gail Naughton
Independent Director
Angus Russell
  • Dividends
  • Splits
  • Insider Activity
No Data
About TXMD
TherapeuticsMD, Inc. is a women's healthcare company engaged in creating and commercializing products for women. The Company is focused on pursuing regulatory approvals and pre-commercialization activities necessary for commercialization of its hormone therapy pharmaceutical products. Its drug candidates used in clinical trials are designed to alleviate symptoms of and reduce health risks resulting from menopause-related hormone deficiencies, including hot flashes, osteoporosis and vaginal discomfort. With its SYMBODA technology, it is developing hormone therapy pharmaceutical products to enable delivery of bio-identical hormones through dosage forms and administration routes. Its product line includes vitaTrue, vitaPearl, vitaMedMD Plus, vitaMedMD One Prenatal Multivitamin, vitaMedMD Plus Rx Prenatal Multivitamin, vitaMedMD One Rx Prenatal Multivitamin, vitaMedMD Iron 21/7, vitaMedMD Vitamin D3 50,000 IU, BocaGreenMD Prena1 Pearl and BocaGreenMD Prena1 Chew.

Webull offers kinds of TherapeuticsMD Inc stock information, including NASDAQ:TXMD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TXMD stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading TXMD stock methods without spending real money on the virtual paper trading platform.